Molecular residual disease (MRD) testing detects cancer recurrence months before traditional imaging Labcorp MRD tests now monitor recurrence risk across stage I–III breast cancer, stage I–IIIA ...

For patients with early-stage triple-negative breast cancer (TNBC), finishing chemotherapy and surgery should feel like the end of the hardest chapter. But for many, it marks the beginning of a ...

Minimal residual disease testing can offer psychological comfort to patients and survivors as well as insight into potential treatment strategies for care providers. Minimal residual disease, or MRD, ...

Minimal residual disease (MRD) testing is poised to transform cancer care, according to John Truesdell, Chief Business Officer at Foresight Diagnostics. In a recent interview with Fierce, Truesdell ...

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation Trials, LLC (AFT) and the Austrian Breast and ...

CITCCA data demonstrate more than 40% of high-risk stage I–III colorectal patients harbor molecular residual disease at clinical landmark, detectable only with ultrasensitive ctDNA testing SAGA ...

Stage 3 colorectal cancer patients with MRD benefit from Celebrex addition to chemotherapy, showing a 40% risk reduction in death for Signatera-positive patients. Celebrex improved disease-free and ...

Roche subsidiary, Foundation Medicine, is boosting its presence in the MRD testing space, which it touts as “one of the ...

The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of ...

Right breast cancer pathway discipline embeds testing early to guide treatment decisions and improve care consistency across health systems.

By Daniella Parra CareDx (Nasdaq: CDNA) said it signed a definitive agreement to acquire Naveris, a commercial-stage precision oncology diagnostics company, for up to $260 million and will close in ...